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1. Introduction 
For decades, schizophrenia was considered exclusively as a biological disorder. As a result, 
pharmacotherapy has been considered as the predominant mode of treatment. 
Antipsychotic medication is indicated for first episode, acute, chronic as well as for 
refractory patients. So much research has been conducted to evaluate the efficacy of 
antipsychotics through clinical studies, randomized controlled trials and meta-analyses. 
Scientific journals are full of research on pharmacotherapy. According to the American 
Psychiatric Association [APA] (2004), a treatment plan for patients with schizophrenia 
should include: 1.- The reduction or elimination of symptoms, 2.- Improving quality of life 
and adaptive functioning, and 3.- Promote and maintain recovery. In the last decades, 
research in the social sciences and psychiatric rehabilitation has produced a considerable 
body of knowledge with respect to psychosocial factors that influence the curse of this 
illness. As a result psychosocial treatments have also been designed and implemented. With 
the beginning of the new century and after more than 60 years of research, there is a 
consensus that biological, psychological and social factors play a very important role in 
understanding and treating schizophrenia. Hence, the biopsychosocial model has been 
considered as the most comprehensive treatment approach for this illness. The treatment of 
schizophrenia has been the focus of changes since the introduction of neuroleptics in the 
1950´s which initiated the transition from mental hospitals to the community, with long-stay 
patients confined in mental institutions going through the deinstitutionalization process, to 
the new millennium where the majority of them are actually living in the community. A 
considerable effort has been carried out in recent years to articulate the scientific basis of the 
treatment for people with schizophrenia. As a result evidence based treatment for 
schizophrenia has recommended that all persons with schizophrenia should receive the 
combination of: 1) optimal dose of antipsychotic medication, 2) psychosocial interventions, 
3) psychoeducation for patients and carers as well as family therapy, and, 4) assertive home-
based management to help prevent and resolve various issues such as: crises, relapse, 
medication adherence, etc, (Drake et al., 2009; Falloon et al., 2004; Fenton & Schooler, 2000; 
Lehman & Steinwachs, 2003; Shean, 2009; Thornicroft & Susser, 2001). In summary, scientific 
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research indicates that the management of schizophrenia should include the following: 1) 
pharmacotherapy, 2) psychosocial interventions, and 3) the integration of these two 
approaches. The aim of this chapter is to describe a research area that integrates 
pharmacological and psychosocial treatment for patients with schizophrenia carried out at 
the National Institute of Psychiatry, in Mexico City. Based upon scientific research, the 
second aim consists on presenting a proposal of this integration on a comprehensive 
treatment approach for schizophrenia patients of a developing country as Mexico.  
2. Pharmacological treatment 
Schizophrenia represents a chronic and debilitating mental disorder that affects about 0.7% of 
general population all over the world (McGrath, 2008), which means approximately 24 million 
people worldwide (World Health Organization [WHO], 2011). In the case of Mexico, with a 
population of 112 million inhabitants, the population at risk between 15-65 years of developing 
schizophrenia is 63.6 millions, a one percent estimate would indicate that approximately 
630,000 individuals suffer schizophrenia as to 2011. Treatment is complex and should always 
be initiated with pharmacological interventions. Antipsychotics are the drugs of choice 
(Freedman, 2005; Geddes, 2000; Kane & Marder, 1993; Kane & McGlashan, 1995; Marder, 2002) 
as they control most of the symptom clusters that characterize this disorder. More than 60 
years ago, Jean Delay and colleagues discovered chlorpromazine (López-Muñoz et al., 2002), a 
then novel sedative compound, and almost at the same time Paul Janssen discovered 
haloperidol (Granger, 1999), a potent neuroleptic compound. Both drugs were shown to be 
useful to relieve psychotic symptoms, and so began a new era in the treatment of psychotic 
disorders, with schizophrenia as the prototype. Emergence of this 2 kind of drugs, 
phenothiazines and butyrophenones, placed the so called conventional antipsychotics as the 
first line treatment for schizophrenia for many decades (Geddes, 2000; Kane & Marder, 1993; 
Kane & McGlashan, 1995; Marder, 2002). Beginning with clozapine some decades ago, but 
mostly for the last 15 to 20 years, new antipsychotic medications have been developed 
(Geddes, 2000; Lehman et al., 2004). The now named atypical antipsychotics (more correctly 
second generation antipsychotics) represent a better said heterogeneus group of drugs (Davis 
et al., 2003; Geddes, 2000; Haddad & Sharma, 2007). These new agents are quite different in 
that, at least most of them, do not generate neuroleptization quite so much as some of the 
conventional medications and in that, most of them are effective antipsychotics with minimal 
or negligible EPS and hiperprolactinemia (García-Anaya et al., 2001, Geddes, 2000; Rosenheck, 
2003). One important issue that distinguishes this group of drugs from conventional 
antipsychotics is the separation of their clinical efficacy from their neurotoxic effects (Posligua, 
1995). Beside this advantages they also appear to have greater effectiveness than conventional 
antipsychotics in treating the so-called negative symptoms of schizophrenia (García-Anaya et 
al., 2001; Leucht, 1999; Posligua, 1995), in controlling other symptom clusters like behavioral 
disturbances, in having an apparent positive impact on neurocognitive functioning (Keefe, 
1999, 2003; Rosenheck, 2003) and on psychosocial functioning (Swartz, 2003; Swartz et al., 
2007), in lowering relapse and rehospitalisation rates (Csernansky & Schuchart, 2002) and in 
promoting a better quality of life for patients (Chung, 2004; Jones, 2006). This relative 
superiority could result from the reduction in side effects, especially EPS, but also maybe from 
a direct pharmacologic effect, that can explain why this group of drugs are now considered 
first line treatment choice and, as so, could have a relevant impact in improving social and 
vocational outcomes of patients with psychotic disorders like schizophrenia.  
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Antipsychotic Chemical Group Usual dose Available since 
Haloperidol* Butyrophenone 5-20 mg/day 70’s 
Chlorpromazine Phenothiazine 25-500 mg/day 70’s 
Sulpiride Benzamide 50-600 mg/day 70’s 
Perphenazine* Phenothiazine 4-60 mg/day 70’s 
Trifluoperazine Phenothiazine 5-50 mg/day 70’s 
Levomepromazine Phenothiazine 25-200 mg/day 70’s 
Clozapine Thienobenzo-diazepine 25-600 mg/day 80’s 
Flupenthixol Thioxanthene 5-20 mg/day 90’s 
Zuclopenthixol Thioxanthene 20-60 mg/day 90’s 
Olanzapine* Thienobenzo-diazepine 5-20 mg/day 90’s 
Risperidone* Benzisoxazole 1-6 mg/day 90’s 
Quetiapine Dibenzothiazepine 300-800 mg/day 90’s 
Ziprasidone* Benzisothiazol 80-160 mg/day 90’s 
Amisulpiride Benzamide 50-400 mg/day 2000’s 
Aripiprazole Dichlorophenyl-piperazine 10-30 mg/day 2000’s 
Sertindole Phenylindole 12-20 mg/day 2000’s 
Paliperidone Benzisoxazole 3-9 mg/day 2000’s 
(*) Available in the Mexican public health system 
Table 1. Oral antipsychotic drugs available in Mexico  
2.1 Introduction and use of antipsychotic drugs in Mexico 
History of Latin American countries use of antipsychotics parallels some socio-cultural and 
economic issues; Some cases like Cuba and some central American countries are 
characterized by having only available some conventional antipsychotics like haloperidol 
and chlorpromazine (González et al., 2004), and, in most Latin American countries, even 
though having second generation antipsychotics available, economic issues have limited 
their use. In Mexico we have had available conventional antipsychotics from the 70’s, 
initiating with the prototypes of the first two classes of this group of drugs: the 
butyrophenone haloperidol and the phenothiazine chlorpromazine, and then some other 
phenothiazine compounds and first generation atypical drugs (Table 1). Some first 
generation antipsychotic drugs like fluphenazine, thioridazine and penfluridol were 
available in Mexico in the past but now they are not available anymore. Some of this 
conventional antipsychotic drugs are frequently used in most public psychiatric hospitals 
and institutions and even some of them are still included in the “Cuadro básico” (Basic 
Table of Medications) of the Mexican public health system (Secretaría de Salud, 1999). 
Second generation antipsychotics were introduced in Mexico in the 80’s with their first 
representative drug, clozapine and then in the 90’s, drugs like olanzapine, risperidone, 
quetiapine and ziprasidone were available. Finally, in the 21th century, four more second 
generation antipsychotic drugs are now available: amysulpiride, aripiprazole, sertindole 
and paliperidone. Some of this second generation antipsychotic drugs, like risperidone and 
olanzapine, are being introduced in the Mexican public health system, so they now are at 
hand for more patients. 
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2.2 Clinical considerations for prescribing antipsychotics 
Once a diagnosis of schizophrenia is established, patient should be started on antipsychotic 
treatment as soon as possible, meanwhile other therapeutic measures are initiated. Election 
of antipsychotic drug by a physician most take into account some issues like illness related 
characteristics, drug efficacy, side effects and cost (Kane & McGlashan, 1995; Leuch, Corves 
et al., 2009), patient characteristics including age, gender, health status, other drugs being 
taken by the patient, history of previous use of any antipsychotic drug and some other 
socio-cultural aspects. In a prospective naturalistic study (Edlinger, 2009), the factors 
influencing physicians' choice of antipsychotic drug therapy in the treatment of patients 
with schizophrenia were investigated; it was concluded that antipsychotic drug side effects 
have a larger influence on the choice of antipsychotic than other factors like demographic or 
illness-related variables, with the exception of the severity of positive symptoms, which did 
influenced decision. As it was mentioned above, in developing countries like most Latin 
American countries, including Mexico, aspects like antipsychotic drug availability and drug 
cost should always be considered when making a choice for any antipsychotic. Some 
general important issues concerning the adequate use of antipsychotic drugs that should 
always be considered every time pharmacological treatment is started on a patient with 
schizophrenia include: 
1. Type of antipsychotic drug: At this time, second generation drugs are usually 
considered as first line treatment for individuals with newly diagnosed schizophrenia 
(Leucht, 1999; Leucht, 2003; Leuch, Corves et al., 2009), even though their heterogeneity 
has brought some concerns about their superiority over conventional drugs (Geddes, 
2000; Leucht, 1999; Leuch, Corves et al., 2009; Marder, 2002), and in between them 
(Leuch, Kommossa et al., 2009). In Mexico and some other developing countries, is not 
rare that some patients could still be started on conventional antipsychotics mostly 
regarding availability and cost-effectiveness issues. The choice for oral, parenteral or 
depot formulations will be considered later. 
2. Recommended dosage of antipsychotic drug: Any antipsychotic drug given to treat a 
schizophrenic patient should be started at the lowest effective level of the 
recommended therapeutic range (Davis & Chen, 2004). Dosage outside of this range 
should be justified and documented always; “rapid neuroleptisation” is not 
recommended, and in case of using rapid loading doses, this manoeuvre should be 
made with extreme caution. Subsequent titration of antipsychotic drug on follow up 
should be made according to clinical response and tolerability, sometimes using blood 
levels as a useful manoeuvre (Citrome & Volavka, 2002).  
3. Antipsychotic drug treatment duration: Treatment should be continued for at least 12 
months, then, just in the eventual situation of the disease remitting fully, drug 
treatment may be ceased gradually over at least 1-2 months. In most cases, however, 
antipsychotic drug treatment should be continued indefinitely, as this stance represents 
the best option for the long standing control of symptoms.  
4. Definition and management of antipsychotic treatment resistance: If a patient with 
schizophrenia has been unresponsive to at least two adequate trials (that is using 
therapeutic doses of the drugs, for enough time to get a response) of two different 
antipsychotic medications, then it can be established the diagnosis of antipsychotic 
treatment resistance. If so, a trial of clozapine should be offered to patients, as this 
second generation antipsychotic has been recognized as the drug of choice for treatment 
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resistant schizophrenic patients (Chakos, 2001; Lehman et al., 2004; Marder, 2002; 
Wahlbeck, 1999).  
5. Switching of antipsychotic drug treatment: Reasons for switching antipsychotic drug 
treatment include lack of clinical response and important side effects (Essock, 2002; 
Lehman et al., 2004; Stroup, 2011) Treatment trial with a first prescribed antipsychotic 
drug should be kept for at least 4-8 weeks before considering the use of another 
antipsychotic medication, and only after optimizing first drug dosage, which could 
mean dose titrating until the maximum recommended (Essock, 2002). Two 
antipsychotic medications at a time, whatever second generation or conventional, 
should not be prescribed together, although this aspect is still controverted (Barnes & 
Paton, 2011; Lehman et al., 2004; Miller & Craig, 2002), with the exception of short 
periods to cover changeover when switching to another antipsychotic. Switching 
strategies of antipsychotic medications include 3 options (Weiden, 2006):  
 Discontinuation: This option consists in abruptly discontinuing the first drug before 
starting the second medication. This method of switching minimizes risk of dosing 
errors and allows closer monitoring for signs of relapse and can be an appropriate 
choice when switching from a conventional antipsychotic to a second generation one or 
from a depot medication to any oral formulation. This method has the inconvenience of 
potentially favoring symptom exacerbation and withdrawal reactions derived from 
discontinuation of the previous antipsychotic.  
 Cross-tapering: This option consists in gradual tapering of the first medication while 
starting and titrating the second antipsychotic drug, with temporal simultaneous 
administration of both the original and the new drug. This method of switching is 
suitable when stable patients are experiencing significant side effects from their 
previous medication. The time elapsed for the cross-titration usually goes between 1 
and 4 weeks (De Nayer et al., 2003) although a slower withdrawal period is convenient 
when switching particular antipsychotics. This option has the inconvenience of 
exposing patients to subtherapeutic dosages of both medications, with risk of relapse.  
 Delayed withdrawal: This option consists in starting a second antipsychotic drug, 
which is titraded to a therapeutic dose, before tapering of the first drug. Keeping the 
patient on a therapeutic dose of the new medication before reducing previous 
medication avoids exposure to subtherapeutic dosages, and may represent the safest 
switching method. This method may be suitable for patients who have not 
accomplished a complete stabilization following a recent relapse and for patients who 
are not having a good adherence to treatment. Using this method should require 
physicians to ensure the crossover is complete, without allowing patients to continue 
with both medications indefinitely. This method has the inconvenience of having 
patients exposed to the side effects of two antipsychotic drugs (Lehman et al., 2004).  
6. Follow-up of patients receiving antipsychotic medication: Routine laboratory and 
clinical monitoring should occur before starting an antipsychotic drug and during 
treatment follow up as well (Marder, 2002; Lehman et al., 2004). According to 
toxicology and potential side effects of the drug of choice, laboratory parameters to 
evaluate may include Complete Blood Count (CBC), Liver Function Tests (LFT), Blood 
Glucose (BG), Cholesterol (Total, HDL and LDL), Triglycerides, Prolactine Blood Level 
(PBL) and Electrocardiogram (EKG). Clinical parameters to evaluate include Blood 
Pressure (BP), Weight, Body Mass Index (BMI) and Waist Circumference (WC).  
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Fig. 1. Therapeutic algorithm for the use of antipsychotic drugs in the treatment of 
schizophrenia 
7. Tolerability and toxicologic aspects of antipsychotics: Beyond the clear differences in 
side effects and toxicologic risks between antipsychotics, either conventional drugs or 
second generation drugs, there are common potential consequences that should be kept 
in mind every time an antipsychotic is prescribed to a schizophrenic patient (Haddad & 
Sharma, 2007; Lehman et al., 2004; Marder, 2002). Parkinsonism and other 
extrapyramidal side effects are common with potent conventional drugs like 
haloperidol and fluphenazine (Ortega-Soto et al., 1998; Ortega-Soto & Valencia, 2001), 
but also with some second generation antipychotics like risperidone (Haddad & 
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Sharma, 2007). Hyperprolactinemia is associated again with potent conventional drugs 
and some second generation drugs like risperidone and amysulpiride (García-Anaya et 
al., 2001; Haddad & Sharma, 2007). Metabolic side effects were originally described 
with some low potency conventional drugs but they were later evidently associated 
with some of the second generation drugs: Weight gain (Allison, 1999; Haddad & 
Sharma, 2007; Newcomer, 2005; Rosenheck, 2003); Hyperlipidemia (Haddad & Sharma, 
2007; Koro, 2002; Newcomer, 2005); Glucose metabolism disturbances (Haddad & 
Sharma, 2007; Henderson, 2005; Newcomer, 2005), and even Diabetes Mellitus (Leslie & 
Rosenheck, 2004; Newcomer, 2005) have been highly associated with clozapine and 
olanzapine, fairly associated with quetiapine and risperidone and lightly associated 
with haloperidol, ziprasidone, aripiprazole, amysulpiride and paliperidone. Sedation is 
usually expected with Chloropromazine, Thioridazine, Clozapine, Olanzapine and 
Quetiapine (Haddad & Sharma, 2007; Lehman et al., 2004; Ortega-Soto & Valencia, 
2001). Prolongation of QT interval (QTc) is at highest risk with thioridazine, ziprasidone 
and sertindole (Haddad & Sharma, 2007; Lehman et al., 2004). Other side effects 
reported in patients receiving antipsychotic drugs include sexual dysfunction, 
anticholinergic symptoms, postural hypotension, agranulocytosis, seizures and 
neuroleptic malignant syndrome (Haddad & Sharma, 2007; Lehman et al., 2004; 
Marder, 2002). Finally, cerebrovascular events have recently been associated with 
second generation antipsychotics (Haddad & Sharma., 2007).  
Antipsychotic Chemical Group Usual dose Available since 
Haloperidol* Butyrophenone 5-60 mg a day 70´s 
Zuclopenthixol Acetate Thioxanthene 50-100 mg q/2-3 d. 90´s 
Olanzapine* Thienobenzo-diazepine 10-30 mg a day 90¨s 
Ziprasidone* Benzisothiazol 10-40 mg a day 90¨s 
(*) Available in Mexican Public Health System 
Table 2. Parenteral antipsychotic drugs for acute states available in Mexico 
Management of acute episodes: Acute states of patients with schizophrenia require 
initiating or adjusting antipsychotic treatment to control new and/or exacervated 
symptoms (Kane & McGlashan, 1995). This episodes are sometimes managed in the 
psychiatric hospital setting (Lehman et al., 2004) A frequent problem found in these acute 
descompensated patients is the lack of conciousness about the need for an acute treatment 
intervention and a lack of disposition for receiving pharmacological treatment as well. So 
patient relatives are often confronted with difficult decisions like taking the patient into a 
closed institution where pharmacologic and other treatment strategies could be initiated 
even without patient cooperation. Under these circumstances, parenteral antipsychotic 
drugs -usually trough intramuscular administration- are very frequently used, as they are 
easier to administrate to patients not accepting treatment, with lower harm risks for them. 
Most of these drugs should be administrated once or more times during a day, as they 
usually have half lives no longer than 24 hours, with the exception of Zuclopenthixol 
(Clopixol Aquphase), which can be administrated every 48 to 72 hrs. These drugs are 
useful for getting a faster control of symptoms and for facilitating treatment continuation. 
Table 2 shows parenteral antipsychotic drugs available in Mexico, used in acute episodes 
of schizophrenic patients. 
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Issues regarding treatment adherence: As we all know now, schizophrenic patients 
should keep pharmacologic treatment in the long term, as far as it has been repeatedly 
demonstrated that a good treatment adherence means a more complete and a more rapid 
control of their symptoms, a low chance for future decompensations, and, in general, a 
more frequent reintegration to society and a better quality of life for them. CATIE and 
other international studies (Lieberman et al., 2005) have shown that about 75% of 
schizophrenic patients stop treatment because of different reasons, including lack of 
clinical response and presence of side effects like sedation, EPS, weight gain, and other 
metabolic disturbances. This so high non-adherence rate to pharmacologic treatment 
means for schizophrenic patients more numerous acute decompensation states, more 
hospitalizations and some other negative consequences. Having said this, one important 
issue on pharmacologic treatment of schizophrenic patients is promoting treatment 
adherence. To reach the goal of keeping schizophrenic patients on treatment, depot 
formulations of antipsychotic drugs are becoming a very useful alternative that favors this 
purpose. This long acting group of antipsychotic drugs allow patients, their families and 
other people taking care of them, to administrate drugs at intervals of 2 to 4 weeks, 
instead of taking them once or even more times a day, thus facilitating and assuring 
adherence to treatment, First depot antipsychotic drug available in Mexico were 
Pipothiazine and Haloperidol Decanoate, then other depot formulations have been 
introduced like the two thioxanthenes Zuclopenthixol Decanoate and Flupenthixol 
Decanoate and more recently Risperidone and Paliperidone Palmitate. 
Antipsychotic Chemical Group Usual dose Available 
since 
Pipothiazine Phenothiazine 25-200 mg/ every 2-4 weeks 70’s 
Haloperidol* Decanoate Butyrophenone 50-150 mg/ every 30 days 80’s 
Zuclopenthixol Decanoate Thioxanthene 200 mg/ every 30 days 90´s 
Flupenthixol Decanoate Thioxanthene 20-100 mg/ every 2-4 weeks 90´s 
Risperidone* Benzisoxazole 25-50 mg/ every 2 weeks 2000´s 
Paliperidone* palmitate Benzisoxazole 39-234 mg/ every 30 days 2000´s 
Table 3. Shows depot antipsychotics now available in Mexico 
Psychothropic drugs other than antipsychotic drugs used in the pharmacologic treatment 
of schizophrenia in Mexico: Beside any antipsychotic drug, and mostly used as adjuvant 
treatment, correcting and complementary pharmacologic treatments for patients with 
schizophrenia, some other classes of drugs are used in the Mexican psychiatric scenarium. 
Litheum and some anticonvulsive drugs like carbamazepine and valproate are frequently 
added to antipsychotic treatment as potentiators of response, especially in patients with 
partial response to antipsychotic drugs alone. Anticholinergic drugs like biperiden and 
trihexifenidile are usually prescribed to correct EPS like parkinsonism as well as beta 
blockers like propranolol, mostly in the presence of acathisia. Sedative-ansiolitic drugs like 
clonazepam, alprazolam and bromazepam are sometimes indicated in cases of anxious 
states accompanying classic symptoms of schizophrenia. Finally, antidepressant drugs are 
used when comorbidity with depressive symptoms is detected. 
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3. Psychosocial treatment 
3.1 Historical perspective of psychosocial treatment 
The introduction of psychosocial treatment for schizophrenia is very much related to the fact 
that psychotic disorders produce dysfunctions, disabilities, and deficits in various domains of 
everyday functioning. Poor psychosocial functioning is a defining characteristic of 
schizophrenia. Social dysfunction is one of the most relevant factors associated with the 
disability of the illness (APA, 1995). Disabilities include difficulties in social and independent 
living skills that act as an impediment for a more normal functioning, (Kopelowicz & 
Liberman, 2003). From all illnesses of mankind, schizophrenia is ranked as the seventh illness 
that causes disability (WHO, 2001). Since schizophrenia patients are often functionally 
impaired, impairments in social functioning could be understood as the inability to take care 
for his/her self, to maintain interpersonal relationships, or the inability to work. These are 
important reasons for considering psychosocial functioning as an important dimension of 
schizophrenia, Deficits in social functioning are a core feature of schizophrenia (Burns & 
Patrick, 2007). Lauriello, Lenroot & Bustillo (2003), state that: “Patients with schizophrenia 
have limitations in their social competence and vocational functioning for a significant period. 
To some extent, these limitations are a consequence of the multiple symptoms and cognitive 
impairments of the disorder”. Role functioning indicates the individual´s abilities to 
demonstrate role performance according to his/hers demands at work, school, social, and 
family situations. Even when psychotic symptoms are in remission with antipsychotic 
medication, approximately two-thirds of schizophrenia patients are unable to accomplish basic 
social roles, such as parenthood, friendship, worker, or being a spouse (Bellack et al., 2007). 
Schizophrenia is characterized by a deterioration, or failure to achieve adequate levels of social 
functioning. Because of the early illness onset many individuals with schizophrenia never 
learned the necessary skills required for adult functioning. The psychosocial environment that 
comprises family factors is another relevant component as demonstrated with a great amount 
of research in the area of Family Expressed Emotion (Leff et al., 1987), and family care of 
schizophrenia (Falloon et al., 1984; Kuipers et al., 2002). One of the most complicated 
challenges in schizophrenia treatment has been to restore impaired psychosocial functioning 
(Swartz et al., 2007), considering that current management has a strong emphasis on living in 
the community (Leucht & Van Os, 2009). The integration of pharmacological and psychosocial 
approaches has been recommended as a means of improving the outcome of patients with 
schizophrenia (Marder, 2000). In addition schizophrenia patients face several problems: 
relapse rates have been reported as high as 70% (McCann et al., 2008; Muller, 2004); even with 
the use of second generation antipsychotics, negatives symptoms still persist (Leucht, Corves 
et al., 2009; Stahl & Buckley, 2007;); approximately 50% meet criteria for substance or drug 
dependence (Bellack et al., 2007); cognitive deficits (Sharma & Harvey, 2000) and poor quality 
of life (Lehman, 1983) should also be considered. Some of these issues remain unresolved.  
Psychosocial treatment aims to improve the management of schizophrenia with the use of 
various techniques such as coping with symptoms, medication adherence, relapse 
prevention, and acquisition of psychosocial skills to improve functioning in certain areas 
such as social relations, work, school, home, recreation, use of mental health facilities, or 
independent living in the community. In the last fifty years a great array of psychosocial 
interventions have been designed such as: social skills training (Bellack et al., 2004; Glynn et 
al., 2002; Liberman, 2007), supported employment (McGurk et al., 2009; Mueser et al., 2001; 
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Tsang, 2001), teaching illness management skills (Atkinson et al., 1996; Birchwood et al., 
1989; Mueser et al., 2002), integrated psychological therapy (Briand et al., 2006; Roder et al., 
2006), assertive community treatment (Bond et al., 2001; Burns et al., 1999; Thornicroft et al., 
1998), cognitive rehabilitation (Bell et al., 2009; Velligan et al., 2006; Vesterager et al., 2011), 
integrated treatment for comorbid substance abuse (Bellack et al., 2006; Ridgely et al., 1990; 
Shaner et al., 2003), family psycho-education (Bauml et al, 2006; Murray & Dixon, 2004; Xia 
et al., 2011), and housing (McCrone & Strathdee, 1994; Harvard Medical School, 2001; 
Trainor et al., 1993). A large body of research supports the efficacy of psychosocial 
treatments, with Reviews (Bellack & Mueser,1993; Benton & Schroeder, 1990; Heinssen et al., 
2000; Huxley et al., 2000; Kopelowicz et al., 2006; Penn et al., 2005); Randomized control 
trials (Glyn et al., 2002; Granholm et al., 2005; Guo et al 2010; Hogarty et al, 2004; Liberman, 
1998); Meta-analysis (Kurtz & Mueser, 2008; Mojtabai et al., 1998; Pilling et al., 2002; Roder 
et al,. 2006) and Treatment recommendations (APA, 2004; Dixon et al., 2010; Kreyenbuhl et 
al., 2009; Lehman & Steinwaschs, 1998, 2003). 
3.2 Introduction of psychosocial treatment in Mexico 
The introduction, application and research in Mexico of psychosocial treatment can be 
divided in two stages: 1) Interventions with acute psychotic hospitalized patients, and 2) 
Interventions with chronic out-patients with schizophrenia.  
3.2.1 Psychosocial treatment for acute psychotic hospitalized patients 
In 1980, a study was conducted to assess the delivery of services of a Psychiatric Hospital for 
acute mentally ill patients, in Mexico City. It was found that the only treatment that patients 
were receiving was antipsychotic medication. As a result a proposal was made that 
considered the convenience to integrate pharmacological and psychosocial rehabilitation 
approaches, as a consequence a pilot study that was carried out between 1980 and 1984. 
Psychosocial treatment was included as a new component, in addition to pharmacological 
treatment, in a clinical trial that integrated a treatment and rehabilitation program for acute 
hospitalized psychotic patients. After patients were clinically stabilized with antipsychotic 
medication, (allowing a two week stabilization period), they participated in daily sessions 
during 4 weeks of the hospitalization period. Patients learned a variety of skills in various 
domains: 1.-Taking care of personal hygiene, appearance and clothing, 2.-Management of 
symptoms and medication, 3.-Occupational skills, 4.-Social skills, 5.-Communication and 
problem solving skills with the family, and 6.-Leisure and sports activities. Verification of 
the skills learned was recorded with the use of a check list. Using a quasi- experimental 
design, an experimental group (n=35) treated with pharmacological and psychosocial 
treatment was compared with a control group (n=35) that was treated with pharmacological 
treatment alone. Psychopathology and global functioning were assessed before and after 
treatment, using the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) and 
the Global Assessment Scale (GAF) (Spitzer et al., 1976). Patients from the experimental 
group demonstrated significant improvements in symptoms such as: anxiety, tension, 
depression, unusual thought content and blunted affect. No improvements were found in 
psychopathology in the control group. These patients experienced more anxiety and tension 
than that reported when they started treatment. Similar results were found in global 
functioning since experimental patients improved their functioning: mean =52 before 
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treatment to a mean=72 at the end of treatment. Control patients showed no improvements 
since they remained at the same level of functioning (51-60) with a mean=59 and a mean=58, 
before and after treatment. It was concluded that an integrated program that combined 
pharmacological and psychosocial treatment was more effective for acute hospitalized 
psychotic patients than pharmacological treatment alone (Valencia, 1988; Valencia, 1991). 
Considering the outcome of this treatment program, it was recommended that the 
combination of pharmacological and psychosocial treatments should be used as the best 
delivery approach for treating these patients. Unfortunately, the rehabilitation work could 
not continue due to the fact of the lack of financial funds and changes in health politics that 
were oriented to alcohol and drugs research at that time. 
3.2.2 Psychosocial treatment for chronic outpatients 
Prior to the initiation of the intervention, we consider a necessity to take into account all 
persons that should be involved in a treatment process. Therefore, we included patients, 
relatives and mental health professionals as relevant participants of this process. Patients 
and relatives were considered as healthy allies and collaborators of the treatment team. 
Relative´s participation was considered as a key element since approximately 90% of our 
patients live with family members (Valencia et al., 2003). Their opinions and ideas served as 
the background for considering the content of a psychosocial treatment program that would 
be offered as an add-on to pharmacotherapy. Hence, we developed a methodology for the 
design of integrated psychosocial and pharmacological interventions, for a developing 
country, as Mexico. The information came from three important sources: a) clinically 
stabilized chronic patients with schizophrenia, b) caregivers living with their ill relatives 
and aware of the patient´s, daily activities, and c) mental health professionals with 
experience in the treatment of schizophrenia patients and their relatives. Information was 
collected considering the clinical needs and psychosocial problems of our patients, as well as 
the caregiver´s needs and demands. The design process included seven stages: 1) 
Identifying clinical and psychosocial problems through two sources: a) an exploratory study 
including patients as participants, so, they would give their opinions about their clinical and 
psychosocial needs, and, b) Using focus groups with patients, relatives and mental health 
professionals (psychiatrists, clinical psychologists, psychiatric social workers, and 
psychiatric nurses), to collect information from these three sources; 2) Establishing a 
consensus about clinical and psychosocial problems from all sources; 3) Designing the 
content of the intervention, and, in addition, with the advice of clinical and social science 
researchers, consider the corresponding methodological issues (experimental design, study 
groups, instruments); 4) Implementation of the treatment program; 5) Determining its 
effectiveness; 6) Follow-up, and 7) Dissemination. All patients were receiving exclusively 
pharmacological treatment. Psychosocial and clinical problems were identified as when 
patients: do not have friends (60-70%); do not have a loving relationship (90-96%); 
unemployed (50-80%); lack of financial sources (80-90%); economically dependent upon 
his/her family (80-90%); do not have good family relations (70-80%); do not know the 
characteristics of the illness (90-95%); do not know his/her diagnosis (55-65%); consider that 
they do not need medication (70-80%); and, consider that they do not need psychotherapy 
(80-90%). In addition, the consensus indicated the presence and persistence of deficits in 
various skills areas that were interfering in the patient´s community functioning. It was 
recommended the importance of developing the following skills: the importance of effective  
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Treatment 
Pharmacological Psychosocial Psychoeducation Family intervention 
 Antipsychotic 
medication 
 First generation 
 Second 
generation 
 Other classes of 
medications: 
Antidepresants 
 Mood 
stabilizers 
 Antianxiety 
medications 
 Symptom 
management 
 Medication 
management 
 Occupation 
 Social relations 
 Couple relations 
 Family relations 
 Money 
management 
 Illness 
management 
 Medication 
management 
 Medication 
compliance 
 Recognition and 
management of 
warning signs of 
relapse 
 The importance of 
medication 
 Medication 
compliance 
 Keeping 
appointments with 
treating psychiatrist 
 Management of 
warning signs of 
relapse 
 Improve 
communication skills 
 Problem solving as 
needed 
Participants 
Patient Patient Relatives Patient and relatives 
Frequency 
Monthly 
appointments 
Weekly sessions, or 
twice a week 
Weekly sessions After psychoeducation 
Duration of sessions 
20 minutes 90 minutes 90 minutes 90 minutes 
Therapeutic modality 
Individual 
consultation 
Group sessions Group sessions for 
all relatives 
Family therapy for the 
patient and his/her 
relatives 
Duration of treatment 
6 months or 1 year 6 months or 1 year 8 sessions or  
12 sessions 
4 sessions or 5 sessions 
Table 4. Proposal of the integration of pharmacological and psychosocial treatment for 
Mexican out-patients with schizophrenia 
communication with the treating psychiatrists, the need to be informed about medication 
benefits, learning medication side effects, learning skills to cope with persistent symptoms, 
planning a long term pharmacological treatment, be willing to collaborate in making 
decision concerning medication, learning skills for avoiding alcohol and drug abuse, 
learning skills to improve adherence to antipsychotic medication, identifying warning signs 
of relapse and developing a relapse preventive plan, developing skills to improve social 
relations, and learning problem-solving skills for improving family relations (Valencia et al., 
2010). The consensus also recommended the inclusion of various therapeutic modalities 
integrated in a comprehensive biopsychosocial service delivery system including: 
pharmacotherapy, psychosocial therapy, psychoeducation, and family therapy. The content 
of these modalities are shown on table 4. After the study protocol was approved by the 
Scientific Research Committee, and for the Ethics Committee of the National Institute of 
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Psychiatry, stages 4) Implementation, and 5) Determining treatment effectiveness were 
tested. A research area was developed where various experimental trials were conducted 
comparing experimental and control groups, or four treatment groups: psychosocial 
treatment, musictherapy, multimodal therapies, and a control group, including 4, 5 or 7 
psychosocial treatment areas, either during a one year or during six months of treatment. In 
all trials pharmacological treatment was delivered once a month, psychosocial treatment 
included one or two sessions per week, 8 or 12 sessions were conducted for 
psychoeducation, 4 or 5 sessions for family therapy, in the last trials, the assessment of the 
level of expressed emotion was also included as an important variable to determine the 
emotional environment in the home as expressed by relatives. (Valencia et al., 2004a, 2004b, 
2006, 2007, 2010) 
In this chapter we describe the results of a research program that integrated 
pharmacological and psychosocial treatments that was carried out at the National Institute 
of Psychiatry in Mexico City. Out-patients diagnosed with schizophrenia according to the 
DSM-IV (APA, 1995) that was corroborated with the CIDI (Robins et al., 1988) participated 
in the study according to the following inclusion criteria: women or men, between 16 to 50 
years, with at least six years of education, living with their relatives in Mexico City or the 
metropolitan area. Patients had to be under pharmacological treatment and therefore 
demonstrate to be clinically stable as regards to their psychotic symptoms according to the 
PANSS within a range of 60-90 before the initiation of treatment. One hundred and fifty six 
out-patients attending the Schizophrenia Clinic were randomly assigned, in an alternate 
order, to two treatment conditions: a study group (n=78), or to a comparison group (n=78). 
Of the 156 patients initially included in the study, 10 from the study group (12.8%) and 17 
from the comparison group (21.7%) corresponding to a total of 17 patients (17.3%) of the 
sample, failed to complete the study, leaving a final sample of 129 patients: n=68, in the 
study group and n=61, in the comparison group. Patients of the study group received 
psychosocial treatment, specifically, psychosocial skills training and psychoeducation for 
their relatives, while the comparison group received the standard pharmacological 
treatment alone. Both groups completed one year of treatments. Pharmacological treatment 
for the two groups under study was provided at the Schizophrenia Clinic of the Institute, 
once a month, during twenty minutes, by two psychiatrists, who prescribed antipsychotics, 
verified medication compliance, keep a record of the attendance to appointments, and 
registered relapse and rehospitalizations. The treating psychiatrists were blind to the two 
treatment conditions. Psychosocial treatment included seven treatment areas as specified in 
Table 4. The aims of the intervention were: 1) facilitate patients’ acquisition of psychosocial 
skills; 2) improve psychosocial and global functioning, 3) prevent relapse and 
rehospitalizations, 4) promote compliance with medication and treatment adherence. A 
team of two therapists trained in psychosocial skills training held weekly group sessions 
during 90 minutes. To carry out the therapeutic work with the patients, therapists had to 
follow the therapist´s manual that describes the training strategies for all sessions (Valencia 
et al., 2001). For acquisition of the skills, a technique known as the “learning activities” was 
utilized and modified for our patients (Valencia et al., 2007). This technique was developed 
and empirically validated for schizophrenia patients (Liberman, 2007; Wallace et al., 1992), 
as well as for Latinos with schizophrenia in the United States (Kopelowicz et al., 2003). A 
check list was also available to verify that patients learned the corresponding skills for each 
treatment area. A research assistant utilized a therapist fidelity evaluation check list to 
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assure that each learning activity included in the training manual was taught competently 
during treatment. Psychoeducation provided information for relatives about the 
management of schizophrenia, coping with the illness, antipsychotic medications and its 
side effects, compliance with medication, and with psychiatric consultations, and 
understanding and management of signs of relapse. This intervention was held during ten 
sessions in a group format. The two groups under study were evaluated before and after 
treatment. The Positive and Negative Syndrome Scale [PANSS], Spanish adaptation, (Kay et 
al., 1990), and the Global Assessment of Functioning Scale [GAF] (APA, 1995), were used to 
assess psychopathology and psychosocial functioning. Relapse, and rehospitalization rates, 
compliance with antipsychotic medication and adherence to treatment were also assessed.  
 Study 
Group 
n = 68 
Comparison 
Groupl 
n = 61 
Gender, n (%)     
 Male 50 (73.5) 47 (77.0) 
 Female 18 (26.5) 14 (23.0) 
Marital status, n (%)     
 Single 65 (95.6) 55 (90.2) 
 Married 2 (2.9) 3 (4.9) 
 Speratated/divorced 1 (1.5) 3 (4.9) 
Occupation, n (%)     
 Employed 9 (13.2) 16 (26.2) 
 Housewife 2 (2.9) 4 (6.6) 
 Student 2 (2.9) 8 (13.1) 
 Unemployed 55 (80.9) 33 (54.1) 
Age, years, 隙博 (s) 29.6 (6.9) 29.5 (7.1) 
Education, years, 隙博 (s) 11.2 (2.1) 11.1 (2.1) 
Age at onset 隙博 (s) 21.6 (6.5) 21.2 (4.6) 
Table 5. Participants demographic and clinical data at baseline 
All participants expressed in a written informed consent their desire to participate in the 
research project. Data analysis included the following: Descriptive and Chi square analysis 
to compare percentages, Student t tests to verify that there were no significant differences 
between the two groups under study in their initial levels of psychopatology, and 
psychosocial functioning, Analysis of variance for repeated measures (ANOVA) to detect 
pre-post differences within and between the two study groups. For the assessment of effect 
size, three levels were considered: small= .25, medium= .50 and large= 1.00 irrespective of 
the sign (+ or -) of the number (Kazdin & Bass, 1999). Standardized estimate of effect sizes 
were calculated using Cohen´s (1977) d formula defined as: d= 1x - 2x / s. Where 1x  and 2x
are the means at baseline and at the end of treatment of the two groups under study, and s is 
the pooled within-group standard deviation (SD). At baseline, no statistically significant 
differences were found between the two groups under study in psychopathology, (PANSS) 
or psychosocial functioning (GAF), or in their doses of antipsychotic medication as 
determined by calculation of chlorpromazine equivalents. Participant´s demographic and 
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clinical data at baseline is shown in table 5. Patients in both treatment conditions were 
similar with no differences on any of these variables, except for the occupational status with 
a minor percentage of unemployed patients in the comparison group.  
   Statistics b 
 Study Group 
n = 68 
Comparison 
Group 
n = 61 
Main 
effect for 
time 
Main 
effect for 
group 
Interaction 
of group 
and time 
PANSSa overall score, 隙博 (s)      
Baseline 92.6 (41.6) 83.5 (33.9) p < .001 -- p < .001 
Post 43.4 (13.0) 55.7 (16.4)    
Effect size -1.2 -.80    
PANSS positivea, 隙博 (s)      
Baseline 21.1 (11.5) 18.3 (9.8) p < .001 -- p < .01 
Post 9.1 (2.8) 11.6 (4.5)    
Effect size -1.0 -.70    
PANSS negativea, 隙博 (s)      
Baseline 24.4 (11.2) 22.4 (9.4) p < .001 -- p < .001 
Post 11.6 (5.2) 15.0 (6.3)    
Effect size -1.1 -.80    
PANSS GPSa, c, 隙博 (s)      
Baseline 47.1 (20.5) 42.8 (16.4) p < .001 -- p < .001 
Post 22.7 (6.0) 29.1 (8.3)    
Effect size -1.2 -.80    
Level of global functionigd 
(GAF) , 隙博 (s)      
Baseline 43.1 (6.4) 43.1 (6.8) p < .001 p < .001 p < .001 
Post 67.0 (9.2) 43.7 (9.2)    
Effect size 3.8 .10    
 a Higher scores indicate more severe symptoms. b Analysis of variance for repeated measures.c GPS, 
General Psychopathology Scale. d Higher scores indicate better global functioning. Effect size levels: 
small=0.25; medium=0.50; large=1.00 
Table 6. Psychopatology and Psychosocial Functioning of the Study and Comparison Group  
When considering the mean change scores, over one year of treatment, the results indicated 
that statistically significant improvements in psychopatology, as rated by the PANSS, were 
observed in positive and negative symptoms, general psychopathology and in total PANSS 
score for both groups under study. Group-by-time analysis demonstrated significantly 
greater improvement in psychopatology in patients of the study group when compared 
with patients receiving standard pharmacological treatment. Comparison of the effect sizes 
were large for the study group on the total PANSS score, positive scale, negative scale, and 
in the general psychopathology scale. Effect sizes were medium for all score scales of the 
comparison group. Significant improvement in psychosocial functioning was also found for 
patients of the study group but not for patients under standard pharmacological care since 
they remained at the same level of functioning (41-50) from baseline to post treatment 
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assessment. Patients of the study group improved two levels of functioning from 41-50 at 
baseline to 61-70 at the end of treatment. Effect size was large for the study group and small 
for the comparison group (Table 6). 
   Statistics b 
 Study 
group 
n = 68 
Comparison 
group 
n = 61 
Main 
effect 
for time 
Main 
effect for 
group 
Interaction 
of group 
and time 
Antipsychotic medication 
dose, a 隙博 (s)      
Baseline 300.8 (286.4) 328.1 (265.4) p < .05   
Post 367.0 (167.5) 408.8 (336.6)    
Dose Range,  
lower – higher 
     
Baseline 14 - 1600 25 – 1200    
Post 29 - 1000 50 – 2400    
a Chlorpromazine equivalents in mg per day. b Analysis of variance for repeated measures. 
Table 7. Antipsychotic dosage of the Study and comparison Group a 
Table 7, illustrates that patients in the two treatment conditions had significant increases in 
the dosage of antipsychotic medication from baseline to post-treatment. At the end of 
treatment, the variability on medication dosage was much higher in patients who received 
standard care. Of the total sample, 65.8% were taking first-generation and 34.2% second-
generation antipsychotics. The three most prescribed medications were: First generation: 
Haloperidol (21.4%), Trifluoperazine (18.8%), and Sulpiride (9.4%). Second generation: 
Risperidone (21.4%), Clozapine (14.3%), and Olanzapine (3.6%). 
 
 Study Group 
n=68 
Comparison Group 
N=61 
 
Variable n % n % X2 
Relapse 8 11.8 17 33.3 p < .01 
Rehospitalizations 3 4.4 7 13.7 -- 
Compliance with medication 62 91.2 40 78.4 -- 
Table 8. Relapse, rehospitalizations and adherence  
Lower relapse (11.8%) and rehospitalization rates (4.4%) were found in the study group 
compared to 33.3% and 13.7% respectively for the group that received medication alone. 
Compliance with antipsychotic medication was higher in the study group (91.2% versus 
78.4%) of the comparison group, (Table 8) 
3.2.3 Integrating pharmacological and psychosocial treatment  
We conclude that a therapeutic approach that included the integration of pharmacological 
and psychosocial treatments for schizophrenia patients can be effective in a developing 
country as Mexico. Patients that received this integrated approach demonstrated significant 
improvements in psychopathology, psychosocial functioning, lower relapse and 
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rehospitalisation rates, and higher compliance with antipsychotic medication, as compared 
with their counterparts that received pharmacotherapy alone. The proposal of integrating 
pharmacological and psychosocial approaches has been described throughout this chapter 
and illustrated in table 4. Of the seven stages developed for designing the interventions, five 
stages were accomplished that ended up with their implementation. We had certain 
limitations with stage 6 since we could not carry out the patient´s “follow-up” due to the 
lack of financial funds. We still have a long way to go since stage 7 ”dissemination” is also a 
pendant task for all schizophrenia patients of our Institute as well for all schizophrenia 
patients in Mexico that would be willing to participate in integrated treatment approaches. 
To accomplish “dissemination”, we could face some complications”, if we consider that only 
0.36% of the Gross Internal Product (GIP) in Mexico is allocated to scientific research, 
compared to 0.49 % in Argentina, 1.11% in Brazil, 2.61% in the United States, 3.22% in Japan, 
and 3.32% in South Korea. It seems that scientific research is not considered a priority in 
Mexico, as a result schizophrenia research neither. However, we have high hopes as being 
optimistic. We expect the necessary support to continue our efforts. When connecting 
clinical practice with scientific research through research protocols, we were able to carry 
out this type of research at the National Institute of Psychiatry whose main goals are to 
conduct research, provide treatment for mental disorders, and training for mental health 
professionals. The Institute belongs to the Coordination of National Research Institutes of 
Mexico that includes 13 Institutes dedicated to treatment and scientific research. Financial 
support for this project was possible with funds from the Institute and a grant from the 
National Council on Science and Technology of Mexico. It was interesting to find out that 
the areas where Mexican patients had psychosocial problem skills were similar to those 
utilized in psychosocial treatment programs in first world countries (Liberman, 2007, Roder 
et al., 2006; Thornicroft & Susser, 2001). It seems that schizophrenia patients share similar 
problems all over the world. Above all, evidence indicates that psychosocial approaches 
when combined with pharmacotherapy results in better outcomes, than either antipsychotic 
medication alone or psychosocial treatment alone. For example, when these two approaches 
are integrated, relapse rates can be reduces as less than 20% (Hogarty, 1993). Understanding 
what bio psychosocial approaches can do for persons with schizophrenia could help us to 
face a new reality that indicates that although there is not a “total cure” for this disease 
research indicates that substantial advances have been made for improving the life of people 
with schizophrenia in the community with the integration of pharmacological and 
psychosocial approaches. 
4. Pharmacological and psychosocial treatment in Latin America 
Research on integrated pharmacological and psychosocial treatment for schizophrenia has 
been carried out mostly in developed countries. We wondered what would be the situation 
in Latin America as to find out what treatments are actually available in this region of the 
world. In order to get a complete picture we searched the following electronic bibliographic 
databases: Medline, Psychiatry, EBM Reviews, PsychINFO-APA, Psychology & Behavioral 
Sciences, Base Salud en Español, CC Clinical Medicine, CC Social and Behabioral Sciences, 
Medic Latina, Elsevier Science Direct, LILACS, SciELO, MEDCaribe, ISI Current Contents, 
PAHO Catalog, The Cochrane Library, Biblioteca Cochrane Plus, Ciencias de la Salud-
BIREME, Organización Mundial de la Salud, WHOLIS, and Science Electronic Library On 
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Line. We used the following key words: schizophrenia, pharmacological treatment, 
antipsychotic medication, psychosocial treatment, psychological therapy, psychosocial 
intervention, psychosocial rehabilitation, psychoeducation, and family therapy. We 
searched the literature with publications in Spanish, Portuguese and English from January 
1970 to July 2011. We found that in addition to Mexico, integrated approaches have been 
carried out in two countries: Brazil (Zimmer et al., 2003, 2006, 2007), and Peru (Sotillo, et al., 
1998). It is worth mentioning that since the early 1950´s, the first generation “conventional” 
antipsychotic medication, and later on, the second generation, or “atypical”, have been 
considered as the only traditional treatment in Latin America for persons suffering from 
schizophrenia. For the year 2011, this approach continues as the customary treatment in 
most Latin American countries. Twenty five years ago, rehabilitation and psychosocial 
treatments were nonexistent in this region of the world; however, in the last twenty years 
some changes have occurred at least in three countries: Brazil (2003-2007); Mexico (1982-
2011) and Peru (1998). The most reasonable explanation why psychosocial treatments have 
not been carried out is because of the lack of economic or financial funds. If clinical services 
still face serious deficits: old and huge hospitals, too many patients and a reduced staff, it is 
not difficult to understand why research on behavioural or psychosocial treatments is 
practically nonexistent. With this scenario there is no doubt that the situation in Latin 
America is quite different than first world countries. We have a long way to go. 
5. Conclusion 
Based upon international evidenced-based practices, treatment recommendations and 
practice guidelines for schizophrenia, an area of research that integrated pharmacotherapy 
and psychosocial therapies was implemented for Mexican patients with schizophrenia. 
Valuable contributions from patients, relatives, mental health professionals, as well as 
cultural considerations were taken into account for the design of the interventions. What is 
good to consider was to find out the effectiveness of these therapeutic modalities as 
described in this chapter as a comprehensive care system for people with schizophrenia in 
Mexico. What is new to consider is that these interventions are available for a developing 
Latin American country. However, reality indicates that the great majority of schizophrenia 
patients in Mexico and Latin America do not receive integrated approaches. We recommend 
the implementation of these therapeutic modalities for all schizophrenia patients in Mexico 
and in Latin America, because patients deserve to receive the best quality of service that 
goes beyond the traditional and exclusively approach of pharmacotherapy. Limitations in 
the implementation in clinical settings as well as problems in translating research into 
everyday practice should be considered (Margison, 2003). Although, antipsychotic 
medication can usually help to stabilize symptoms, impairments and disabilities still persist. 
Wouldn’t it be nice if medication could help to restore the individual suffering from 
schizophrenia, to “normal” life, and regain his/her ability to function in society, to make up 
for lost time. However, patients could never learn new skills for their survival in the “real 
world” by taking medication. They need medication as well as psychosocial services. Living 
in the community independently and successfully should be a goal to pursue. The purpose 
is the re-integration of persons with schizophrenia in the community. Future research 
should focus on an independent living-beyond medication- in the community. To reach this 
goal, patients should go through various conditions that include new and resent proposals: 
1) the achievement of “symptomatic remission” (Andreasen et al., 2005), with the use if 
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antipsychotic medication. 2) psychosocial improvements, such as “psychosocial remission”, 
(Barak et al., 2010), with psychosocial approaches, and, 3) the combination of these two 
variables that would led to “recovery” (Leucht & Lasser, 2006; Liberman, et al., 2002; 
Liberman & Kopelowicz, 2005; Liberman, 2008; Torgalsboen & Rund 2010). Understanding 
“functional recovery”as the ultimate goal for an independent living in the community. To 
complete the puzzle, the family must be considered as an important component. Patients 
and relatives can become active participants in the “recovery process” since it has been 
demonstrated that with the use of psychoeducation and family approaches, expressed 
emotion can be reduced, so patients and their carers could live in a less stressful 
psychosocial environment. Enhanced monitoring practices could also help for patients, 
relatives and the treatment team, to be in close contact, as demonstrating “good therapeutic 
alliance” to intervene when necessary, and also verifying that patients are not only “getting 
well”, but also “staying well” in the community (Yeomans et al., 2010). This general picture 
indicates that some patients with schizophrenia are still unable to cope with tasks such as 
having friends, holding a job or living independently. Others have demonstrated that they 
could experience periods of symptomatic relief and enhanced functioning as being “in 
recovery”, considering the notion that recovering from schizophrenia is possible. Recovery 
should be a goal to pursue for the future. 
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